NASDAQ:TVTX

Travere Therapeutics (TVTX) Stock Forecast, Price & News

$8.94

-0.04 (-0.45%)

(As of 09/29/2023 ET)

Compare

Today's Range: $8.94
▼
$9.28
50-Day Range: $7.64
▼
$17.25
52-Week Range: $7.00
▼
$26.55

Volume: 1.09 million shs
Average Volume: 2.43 million shs
Market Capitalization: $670.59 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $21.46

Travere Therapeutics MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.67 Rating Score
Upside/Downside: 140.1% Upside
$21.46 Price Target
Short Interest: Bearish
12.05% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.09
Based on 7 Articles This Week
Insider Trading: Selling Shares
$98,954 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($5.11) to ($4.15) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.10 out of 5 stars

Medical Sector

523rd out of 972 stocks

Pharmaceutical Preparations Industry

248th out of 458 stocks

4.3

Analyst's Opinion

Consensus Rating
Travere Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 10 buy ratings, 5 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $21.46, Travere Therapeutics has a forecasted upside of 140.1% from its current price of $8.94.
Amount of Analyst Coverage
Travere Therapeutics has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

1.0

Short Interest

Percentage of Shares Shorted
12.05% of the outstanding shares of Travere Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Travere Therapeutics has a short interest ratio ("days to cover") of 6.7.
Change versus previous month
Short interest in Travere Therapeutics has recently increased by 5.73%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Travere Therapeutics does not currently pay a dividend.
Dividend Growth
Travere Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for TVTX.

2.8

News and Social Media Coverage

News Sentiment
Travere Therapeutics has a news sentiment score of 0.09. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 7 news articles for Travere Therapeutics this week, compared to 3 articles on an average week.
Search Interest
11 people have searched for TVTX on MarketBeat in the last 30 days. This is an increase of 1,000% compared to the previous 30 days.
MarketBeat Follows
2 people have added Travere Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Travere Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $98,954.00 in company stock.
Percentage Held by Insiders
Only 3.75% of the stock of Travere Therapeutics is held by insiders.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Travere Therapeutics are expected to grow in the coming year, from ($5.11) to ($4.15) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Travere Therapeutics is -1.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Travere Therapeutics is -1.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Travere Therapeutics has a P/B Ratio of 13.34. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Travere Therapeutics (NASDAQ:TVTX) Stock

Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy; and TVT-058, a novel investigational human enzyme replacement candidate, which is in Phase I/II clinical trials for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and patient advocacy organizations, CDG Care, and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

TVTX Price History

30 days | 90 days | 365 days | Advanced Chart

TVTX Stock News Headlines

October 1, 2023 | americanbankingnews.com

Travere Therapeutics (NASDAQ:TVTX) Rating Reiterated by Wedbush

September 26, 2023 | markets.businessinsider.com

Stifel Nicolaus Sticks to Their Hold Rating for Travere Therapeutics (TVTX)

October 1, 2023 | Stansberry Research (Ad)

U.S. "Shadow Banks" About to Blow up again?

Analyst who called Lehman crash says our biggest calamities (1907, 1929, 2007, etc) all start in the same spot--and it’s about to happen again. More here.

September 26, 2023 | finance.yahoo.com

Travere Therapeutics to Present Abstracts at the 17th International Symposium on IgA Nephropathy (IIGANN 2023)